Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03219307 · ClinicalTrials.gov registry record · Phase 3
NOVOCART 3D Treatment Following Microfracture Failure
A Phase 3 study of Articular Cartilage Defect, sponsored by Aesculap Biologics.
- Active
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT03219307 is a Phase 3 study of Articular Cartilage Defect that is active but no longer recruiting, run by Aesculap Biologics. The registered enrollment target is 30 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT03219307, a Phase 3 study of Articular Cartilage Defect, is active but no longer recruiting, sponsored by Aesculap Biologics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is prospective single arm extension study of protocol AAG-G-H-1220. It is open only to participants of AAG-G-H-1220 randomized to the Microfracture treatment group.
Conditions Studied
Interventions
- COMBINATION_PRODUCT NOVOCART 3D
Study Locations (5)
Illinois
- Rush University Medical Center - Chicago
Ohio
- Ohio State University Wexner Medical Center - Columbus
Utah
- Alpine Orthopaedics - North Logan
Alberta
- University of Alberta - Edmonton
Nova Scotia
- Dalhousie University - Halifax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-11-30 |
| Est. Completion | 2029-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03219307
The ClinicalTrials.gov registry entry for NCT03219307 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aesculap Biologics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Articular Cartilage Defect appearing as the primary indexed condition, and to 1 intervention - of which NOVOCART 3D is the first listed.
NCT03219307 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Ohio, Utah.
Frequently Asked Questions
What is clinical trial NCT03219307 about?
NCT03219307 is a clinical study titled "NOVOCART 3D Treatment Following Microfracture Failure". This study is prospective single arm extension study of protocol AAG-G-H-1220. It is open only to participants of AAG-G-H-1220 randomized to the Microfracture treatment group.
What is the current status of trial NCT03219307?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2018-11-30. Estimated completion is 2029-01.
What conditions does trial NCT03219307 study?
This clinical trial studies the following conditions: Articular Cartilage Defect.
What interventions are being tested in trial NCT03219307?
The interventions under investigation include: NOVOCART 3D (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03219307?
This trial is sponsored by Aesculap Biologics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03219307 being conducted?
This trial has 5 study locations across Illinois, Ohio, Utah, Alberta, Nova Scotia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Articular Cartilage Defect
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.